{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":11,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":11,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"7bfd0db550be","filters":{"venue":"Kidney Cancer"}},"results":[{"id":"W2605821659","doi":"10.3233/kca-160002","title":"Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)","year":2017,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"Foundation Medicine; Astellas Pharma; Eisai; National Comprehensive Cancer Network; GlaxoSmithKline; Exelixis; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Renal cell carcinoma; Medicine; Chromophobe cell; Oncology; Targeted therapy; Cancer; Internal medicine; Clear cell","authors":[{"name":"Steven Yip","is_ca":true},{"name":"José Manuel Ruiz Morales","is_ca":false},{"name":"Frede Donskov","is_ca":false},{"name":"Anna Paola Fraccon","is_ca":false},{"name":"Umberto Basso","is_ca":false},{"name":"Brian I. Rini","is_ca":false},{"name":"Jae‐Lyun Lee","is_ca":false},{"name":"Georg A. Bjarnason","is_ca":true},{"name":"Hao‐Wen Sim","is_ca":true},{"name":"Benoit Beuselinck","is_ca":false},{"name":"Ravindran Kanesvaran","is_ca":false},{"name":"James Brugarolas","is_ca":false},{"name":"K. Koutsoukos","is_ca":false},{"name":"Simon Fu","is_ca":false},{"name":"Takeshi Yuasa","is_ca":false},{"name":"Ian D. Davis","is_ca":false},{"name":"Ajjai Alva","is_ca":false},{"name":"Christian Kollmannsberger","is_ca":true},{"name":"Toni K. Choueiri","is_ca":false},{"name":"Daniel Y.C. Heng","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05602898733680911,"gpt":0.3205884367928813,"spread":0.2645594494560722,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002418914,0.0001508681,0.0005406219,0.001013667,0.0002467929,0.0009190404,0.0003494797,0.0002395363,0.0007187726],"category_scores_gemma":[0.005628949,0.00009627504,0.000525562,0.002088536,0.0002285821,0.0004549129,0.0007382667,0.000387471,0.0001594483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008590651,"about_ca_system_score_gemma":0.0007321729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006165,"about_ca_topic_score_gemma":0.01174831,"domain_scores_codex":[0.9980565,0.0005539221,0.0002623231,0.000344299,0.0006106284,0.0001723201],"domain_scores_gemma":[0.9955727,0.0008740054,0.002112612,0.0003479412,0.0006762382,0.0004164542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007983519,0.00003855138,0.9858873,0.0001444946,0.0003758567,0.00005060307,0.00008595076,0.0003294223,0.000160966,0.00009536937,0.002315185,0.009717843],"study_design_scores_gemma":[0.00006982948,0.0002765571,0.9940308,0.0000991757,0.0003759713,0.0004890919,0.0002348585,0.0006126694,0.0002920613,0.00008233717,0.003422368,0.00001430683],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739875,0.003739764,0.0003108741,0.0002989,0.00002088164,0.000044806,0.02006988,0.000018105,0.001509377],"genre_scores_gemma":[0.9785539,0.0008941852,0.0002120169,0.0001175261,0.0000280493,0.00002517305,0.02006133,0.00001075077,0.00009721022],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006165,"threshold_uncertainty_score":0.01279265,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787239315","doi":"10.3233/kca-170020","title":"Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)","year":2018,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Pazopanib; Sunitinib; Axitinib; Sorafenib; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Temsirolimus; Proportional hazards model; Targeted therapy; Retrospective cohort study; Urology; Surgery; Cancer; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors","authors":[{"name":"Igor Stukalin","is_ca":false},{"name":"J. Connor Wells","is_ca":true},{"name":"Anna Paola Fraccon","is_ca":false},{"name":"Felice Pasini","is_ca":false},{"name":"Camillo Porta","is_ca":false},{"name":"Aly‐Khan A. Lalani","is_ca":false},{"name":"Sandy Srinivas","is_ca":false},{"name":"I. Alex Bowman","is_ca":false},{"name":"James Brugarolas","is_ca":false},{"name":"Jae‐Lyun Lee","is_ca":false},{"name":"Frede Donskov","is_ca":false},{"name":"Benoit Beuselinck","is_ca":false},{"name":"Aristotelis Bamias","is_ca":false},{"name":"Brian I. Rini","is_ca":false},{"name":"Hao‐Wen Sim","is_ca":true},{"name":"Neeraj Agarwal","is_ca":false},{"name":"Sun Young Rha","is_ca":false},{"name":"Ravindran Kanesvaran","is_ca":false},{"name":"Toni K. Choueiri","is_ca":false},{"name":"Daniel Y.C. Heng","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05521137413412077,"gpt":0.3092914079217557,"spread":0.2540800337876349,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004604186,0.0003266493,0.001060963,0.001867569,0.0002717923,0.001546451,0.0007301985,0.000452062,0.001587418],"category_scores_gemma":[0.010792,0.0001347124,0.001222012,0.00508631,0.0001779637,0.0005863992,0.001199122,0.0004893647,0.0004156455],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536076,"about_ca_system_score_gemma":0.001506478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02321007,"about_ca_topic_score_gemma":0.02423688,"domain_scores_codex":[0.9965012,0.0009766852,0.0005832195,0.0006169212,0.001026626,0.0002953067],"domain_scores_gemma":[0.9849781,0.003241824,0.007406731,0.00138223,0.002028837,0.0009621989],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002076155,0.00005921413,0.9760453,0.0004710041,0.0009756306,0.00007194723,0.00006962461,0.0009616922,0.0001240134,0.00008657348,0.006881686,0.01217719],"study_design_scores_gemma":[0.0002597299,0.0002592521,0.9871683,0.000228933,0.0008065538,0.0002912566,0.0001878456,0.001811591,0.0002688365,0.00005939489,0.008634985,0.00002341021],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8199022,0.00905683,0.0004319822,0.0007184168,0.00004699535,0.0001140523,0.1673051,0.00006759397,0.00235689],"genre_scores_gemma":[0.8589271,0.001682964,0.0004751321,0.0002563439,0.00004313633,0.00007722337,0.1382104,0.00002463398,0.0003029857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02321007,"threshold_uncertainty_score":0.04614997,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2741346996","doi":"10.3233/kca-170010","title":"Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward","year":2017,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"ECOG-ACRIN Cancer Research Group; European Association of Urology; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Perioperative; Nephrectomy; Oncology; Adjuvant therapy; Internal medicine; Clinical trial; Surgery; Immunotherapy; Chemotherapy; Kidney; Cancer","authors":[{"name":"Lauren C. Harshman","is_ca":false},{"name":"Charles G. Drake","is_ca":false},{"name":"Naomi B. Haas","is_ca":false},{"name":"Judith Manola","is_ca":false},{"name":"Mäneka Puligandla","is_ca":false},{"name":"Sabina Signoretti","is_ca":false},{"name":"David Cella","is_ca":false},{"name":"Rajan T. Gupta","is_ca":false},{"name":"Rupal S. Bhatt","is_ca":false},{"name":"Eliezer M. Van Allen","is_ca":false},{"name":"Primo N. Lara","is_ca":false},{"name":"Toni K. Choueiri","is_ca":false},{"name":"Anil Kapoor","is_ca":true},{"name":"D.Y.C. Heng","is_ca":false},{"name":"Michael A.S. Jewett","is_ca":true},{"name":"Daniel J. George","is_ca":false},{"name":"M. Dror Michaelson","is_ca":false},{"name":"Michael A. Carducci","is_ca":false},{"name":"David F. McDermott","is_ca":false},{"name":"Mohamad E. Allaf","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07852159444762236,"gpt":0.3996867316737452,"spread":0.3211651372261229,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008859385,0.0004703305,0.0007734992,0.0004985131,0.000667365,0.00333323,0.001215142,0.002212318,0.004167938],"category_scores_gemma":[0.006661131,0.0001907009,0.001196709,0.000542185,0.001974393,0.004894771,0.001861083,0.007790636,0.001214122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001347017,"about_ca_system_score_gemma":0.006016739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001122112,"about_ca_topic_score_gemma":0.004066983,"domain_scores_codex":[0.9982415,0.0009265905,0.0001189056,0.0001905516,0.0002630688,0.0002593014],"domain_scores_gemma":[0.9934551,0.002677702,0.0006307588,0.000398923,0.001179937,0.00165752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001681979,0.002006661,0.003331697,0.002812476,0.0001790328,0.0003379402,0.0005124075,0.001197874,0.004356458,0.03917209,0.0686126,0.8757986],"study_design_scores_gemma":[0.002114935,0.009359027,0.009533665,0.00635505,0.0004302176,0.001590722,0.001955702,0.00201423,0.005274979,0.06966347,0.8914828,0.0002252125],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.02346526,0.3603956,0.01735955,0.5653896,0.01775401,0.0003658956,0.0002303128,0.0003484458,0.01469145],"genre_scores_gemma":[0.1941892,0.4736914,0.05848129,0.2333165,0.03070982,0.0008181901,0.0006234681,0.0002396608,0.007930455],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.008859385,"threshold_uncertainty_score":0.04685342,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2997361961","doi":"10.3233/kca-190077","title":"Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer","year":2019,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Dosing; Medicine; Toxicity; Vascular endothelial growth factor; Cancer; Drug; Tyrosine-kinase inhibitor; Adjuvant; Oncology; VEGF receptors; Pharmacology; Internal medicine","authors":[{"name":"Ambika Parmar","is_ca":true},{"name":"Georg A. Bjarnason","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0229485505792703,"gpt":0.3077115109704465,"spread":0.2847629603911762,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001896546,0.0002309802,0.0007935317,0.0004028572,0.0001874647,0.0005735988,0.000440646,0.0002590617,0.000547788],"category_scores_gemma":[0.002089405,0.0001034633,0.0005894874,0.0003167837,0.0002139712,0.0003816623,0.0002363034,0.0006662716,0.0001572282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009218244,"about_ca_system_score_gemma":0.0005554296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003261776,"about_ca_topic_score_gemma":0.001249418,"domain_scores_codex":[0.999212,0.0003940996,0.0001074608,0.00005682217,0.0001939374,0.00003567702],"domain_scores_gemma":[0.9990773,0.0004511634,0.0003518265,0.00003093503,0.00005612691,0.00003267603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002120043,0.0003987398,0.004720559,0.002601245,0.0002881874,0.0001927118,0.0001334896,0.006447165,0.01235565,0.001587671,0.003108814,0.9660457],"study_design_scores_gemma":[0.004847916,0.05125666,0.1393866,0.005877248,0.003357441,0.01177386,0.0005468262,0.01667211,0.06305546,0.01454901,0.6883451,0.0003318196],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2019039,0.7505059,0.02483791,0.006181257,0.0007520215,0.0004895915,0.0001661536,0.0001981968,0.01496512],"genre_scores_gemma":[0.6227665,0.3450082,0.02489482,0.00198287,0.001565359,0.0003509006,0.00020932,0.0001187986,0.003103311],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.001896546,"threshold_uncertainty_score":0.01003003,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3135371333","doi":"10.3233/kca-210110","title":"Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"CancerCare Manitoba; St Joseph's Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Western University; Princess Margaret Cancer Centre; University of Calgary; Centre hospitalier universitaire de Québec; London Health Sciences Centre; Alberta Health Services; McMaster University; University of Manitoba; Juravinski Cancer Centre; Université Laval; University of Alberta","funders":"Genentech; Ipsen; Astellas Pharma; Eisai; Karyopharm Therapeutics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Exelixis; GlaxoSmithKline","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Kidney cancer; Internal medicine; Cancer; Oncology; Tyrosine-kinase inhibitor; Population; Urology; Surgery; Gastroenterology","authors":[{"name":"Han‐Bo Zhang","is_ca":true},{"name":"Naveen S. Basappa","is_ca":true},{"name":"Sunita Ghosh","is_ca":true},{"name":"Isaiah Joy","is_ca":true},{"name":"Aly‐Khan A. Lalani","is_ca":true},{"name":"Aaron R. Hansen","is_ca":true},{"name":"Daniel Y.C. Heng","is_ca":true},{"name":"Vincent Castonguay","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":false},{"name":"Eric Winquist","is_ca":true},{"name":"Lori Wood","is_ca":true},{"name":"Georg A. Bjarnason","is_ca":true},{"name":"Rodney H. Breau","is_ca":true},{"name":"Anil Kapoor","is_ca":true},{"name":"Jeffrey Graham","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02726936905650948,"gpt":0.2753342238878853,"spread":0.2480648548313758,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003523847,0.0001855758,0.0004535638,0.0006208876,0.0006410662,0.001067449,0.0005389472,0.0004031818,0.002470037],"category_scores_gemma":[0.01176773,0.0001335837,0.0003931398,0.002401715,0.0004984592,0.0005802106,0.000789837,0.0004384828,0.0004563196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007190917,"about_ca_system_score_gemma":0.006598365,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3911007,"about_ca_topic_score_gemma":0.4063764,"domain_scores_codex":[0.9974859,0.0006929868,0.0003146669,0.000286493,0.0009513324,0.0002686667],"domain_scores_gemma":[0.9873076,0.002516389,0.004607245,0.000428931,0.003131141,0.00200862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008473475,0.0004525366,0.912169,0.0007259302,0.0003017051,0.0003663078,0.001642796,0.001037993,0.0006552432,0.0001542877,0.01143365,0.06258707],"study_design_scores_gemma":[0.0009284683,0.001727033,0.9789514,0.0001584815,0.000261721,0.0003906774,0.001178902,0.001082563,0.0005615351,0.0000590161,0.01464074,0.00005953362],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761595,0.004310177,0.0001957476,0.001397757,0.00002158437,0.0001929755,0.01382523,0.00002922828,0.003867774],"genre_scores_gemma":[0.9871532,0.001735955,0.0004330152,0.0005668967,0.00004102187,0.0000714459,0.009304246,0.00001629554,0.0006777945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6088993,"threshold_uncertainty_score":0.7776485,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4396814048","doi":"10.3233/kca-230025","title":"Patient Selection for Active Surveillance for Small Renal Masses: A Systematic Review of the Literature","year":2024,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Concordance; Systematic review; Meta-analysis; Comorbidity; MEDLINE; Internal medicine; Cochrane Library; Oncology; Intensive care medicine","authors":[{"name":"Alfredo Distante","is_ca":false},{"name":"Riccardo Bertolo","is_ca":false},{"name":"Riccardo Campi","is_ca":false},{"name":"Selçuk Erdem","is_ca":false},{"name":"Anna Caliò","is_ca":false},{"name":"Carlotta Palumbo","is_ca":false},{"name":"Nicola Pavan","is_ca":false},{"name":"Chiara Ciccarese","is_ca":false},{"name":"Umberto Carbonara","is_ca":false},{"name":"Michele Marchioni","is_ca":false},{"name":"Eduard Roussel","is_ca":false},{"name":"Zhenjie Wu","is_ca":false},{"name":"Peter F.A. Mulders","is_ca":false},{"name":"Stijn Muselaers","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03505213495838975,"gpt":0.3362367575413587,"spread":0.3011846225829689,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01223372,0.001373776,0.008904601,0.009549707,0.0005927071,0.00229977,0.001698947,0.001648645,0.003749228],"category_scores_gemma":[0.05284845,0.0008540335,0.009418945,0.009833733,0.0009266426,0.001896791,0.001333789,0.0009280342,0.0002368748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002980531,"about_ca_system_score_gemma":0.009669646,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006297452,"about_ca_topic_score_gemma":0.01893386,"domain_scores_codex":[0.9875306,0.004612629,0.005210184,0.000861984,0.001534245,0.0002504147],"domain_scores_gemma":[0.9513904,0.03717976,0.007597271,0.0006010913,0.002850754,0.0003806844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002870928,0.00001250408,0.00206123,0.9600885,0.01595901,0.0001235736,0.0002280885,0.00007964834,0.0001210655,0.0001077443,0.0008973667,0.02003429],"study_design_scores_gemma":[0.0004446642,0.0002488177,0.007948825,0.8348639,0.1463869,0.0004997168,0.0004385149,0.00011084,0.0001689146,0.0002967569,0.008549024,0.00004307502],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002885343,0.995041,0.0002300734,0.0003429599,0.00009878049,0.0004811253,0.0006752359,0.00001029903,0.000235313],"genre_scores_gemma":[0.05386268,0.9416831,0.001303702,0.0009801374,0.000130323,0.001264936,0.0006526387,0.00001017507,0.0001123031],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01223372,"threshold_uncertainty_score":0.06469887,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2996252896","doi":"10.3233/kca-190075","title":"Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and <sup>99m</sup> Tc-MDP Bone Scan in a Prospective Clinical Trial","year":2019,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Renal cell carcinoma; Radiology; PET-CT; Clinical trial; Nuclear medicine; Computed tomography; Oncology; Internal medicine","authors":[{"name":"Elizabeth H. Dibble","is_ca":false},{"name":"Sasha Kravets","is_ca":false},{"name":"Su–Chun Cheng","is_ca":false},{"name":"Christopher G. Sakellis","is_ca":false},{"name":"Kathryn P. Gray","is_ca":false},{"name":"Amanda Abbott","is_ca":false},{"name":"Dominick Bossé","is_ca":true},{"name":"Mark M. Pomerantz","is_ca":false},{"name":"Bradley A. McGregor","is_ca":false},{"name":"Lauren C. Harshman","is_ca":false},{"name":"M. Dror Michaelson","is_ca":false},{"name":"Rana R. McKay","is_ca":false},{"name":"Toni K. Choueiri","is_ca":false},{"name":"Katherine M. Krajewski","is_ca":false},{"name":"Heather A. Jacene","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02198469567389538,"gpt":0.3223716724288983,"spread":0.3003869767550029,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004828047,0.001034521,0.00194826,0.0003124353,0.000334438,0.001125103,0.0006512878,0.001463892,0.001239299],"category_scores_gemma":[0.003607466,0.0004830868,0.001435445,0.0005007805,0.0007657792,0.0008021107,0.0003680619,0.00157886,0.0003711932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006568459,"about_ca_system_score_gemma":0.0009388417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005199584,"about_ca_topic_score_gemma":0.001054511,"domain_scores_codex":[0.9981322,0.001323215,0.000136175,0.0001951365,0.0001185841,0.00009472112],"domain_scores_gemma":[0.9973013,0.0009365628,0.0007636137,0.0001693637,0.0001454958,0.0006836538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.930371,0.005018132,0.03350955,0.0003778848,0.001100368,0.0001124577,0.00008554678,0.0007024111,0.003232772,0.00004585991,0.0001970886,0.02524691],"study_design_scores_gemma":[0.4979774,0.3896757,0.1005045,0.0001433773,0.002819685,0.0005411721,0.00009656203,0.003520302,0.00261208,0.0001722646,0.001875911,0.00006099437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944605,0.003768898,0.0002093656,0.0002372106,0.00005130963,0.000680824,0.0001561641,0.00001656584,0.000419231],"genre_scores_gemma":[0.9965367,0.001317255,0.0005400433,0.0002299479,0.0001255447,0.000678791,0.0003809248,0.000005283647,0.000185501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004828047,"threshold_uncertainty_score":0.0255335,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200092447","doi":"10.3233/kca-210117","title":"Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Exelixis; University of Texas Southwestern Medical Center; Burroughs Wellcome Fund","keywords":"Cabozantinib; Medicine; Disease; Renal cell carcinoma; Cancer research; Oncology; Internal medicine; Urology; Pharmacology","authors":[{"name":"Akanksha Sharma","is_ca":false},{"name":"Roy Elias","is_ca":false},{"name":"Alana Christie","is_ca":false},{"name":"Noelle S. Williams","is_ca":false},{"name":"Iván Pedrosa","is_ca":false},{"name":"Georg A. Bjarnason","is_ca":true},{"name":"James Brugarolas","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01581873338030816,"gpt":0.2664854274567906,"spread":0.2506666940764825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001092277,0.0001575819,0.0003046208,0.0001919094,0.0003380822,0.0003558083,0.0001967825,0.0002119538,0.0007447781],"category_scores_gemma":[0.001639786,0.00007267088,0.0004221934,0.0002820502,0.0002452647,0.000231328,0.0002739989,0.0004944293,0.0001135918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001165965,"about_ca_system_score_gemma":0.0004021042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001213424,"about_ca_topic_score_gemma":0.002234891,"domain_scores_codex":[0.99941,0.0001843412,0.00007990148,0.0001263841,0.0001411671,0.00005811211],"domain_scores_gemma":[0.9985876,0.0005140163,0.000552221,0.0001102697,0.00008676498,0.0001491615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"case_report","study_design_scores_codex":[0.006870414,0.001655684,0.8877087,0.0002061564,0.0003940368,0.003100117,0.0003726978,0.003048661,0.01595935,0.0001408025,0.0004251653,0.08011811],"study_design_scores_gemma":[0.0004899287,0.01530871,0.9582416,0.00002712926,0.0003116078,0.008601553,0.0001642983,0.003751814,0.01072323,0.000148915,0.002207729,0.00002349051],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983615,0.0004859366,0.0002840429,0.00004671164,0.000002740365,0.00003081597,0.0000517065,0.000005422483,0.0007311185],"genre_scores_gemma":[0.9995499,0.00007789269,0.0001966796,0.00003372758,0.000006368681,0.000007404792,0.00005492742,0.00000142716,0.00007167118],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001213424,"threshold_uncertainty_score":0.008459747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3014903654","doi":"10.3233/kca-190076","title":"First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Renal cell carcinoma; Medicine; Oncology; Nivolumab; Cancer research; Internal medicine; Immunotherapy; Cancer","authors":[{"name":"Myuran Thana","is_ca":true},{"name":"Lori Wood","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06481327969497024,"gpt":0.3352854722955182,"spread":0.270472192600548,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004336463,0.001234304,0.007494174,0.005918319,0.0004369935,0.00147384,0.001505359,0.001400326,0.005143279],"category_scores_gemma":[0.01418054,0.0006260665,0.007310719,0.006696488,0.000467778,0.001351318,0.0008525086,0.0008927772,0.0003132169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002375332,"about_ca_system_score_gemma":0.007540786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006465398,"about_ca_topic_score_gemma":0.0207123,"domain_scores_codex":[0.9968535,0.001128211,0.001023813,0.0002685899,0.000596169,0.0001296923],"domain_scores_gemma":[0.9908818,0.005434606,0.002275872,0.0001155381,0.001126797,0.0001654816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002457884,0.00001697315,0.0004818994,0.9659614,0.01134321,0.00005947097,0.000065678,0.00008691657,0.0001189556,0.00008942657,0.001211661,0.02031859],"study_design_scores_gemma":[0.0006535,0.0004542007,0.005119664,0.8166679,0.1585616,0.0003863,0.0001757839,0.0001457175,0.0001904371,0.0002105683,0.01739367,0.00004056486],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008434472,0.9981147,0.00008610498,0.000158505,0.00006744132,0.000204937,0.0003223084,0.000005726103,0.0001968752],"genre_scores_gemma":[0.01426988,0.9839883,0.0003830488,0.0004243609,0.00007353393,0.0004674634,0.0002763867,0.000003090502,0.0001139007],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007494174,"threshold_uncertainty_score":0.02293366,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4401252649","doi":"10.3233/kca-240005","title":"Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy","year":2024,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; University of Calgary","funders":"Ipsen","keywords":"Cabozantinib; Renal cell carcinoma; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Internal medicine; Cancer research; Cancer; Receptor","authors":[{"name":"Daniel Yick Chin Heng","is_ca":true},{"name":"Gurjyot K. Doshi","is_ca":false},{"name":"Pascale Dutailly","is_ca":false},{"name":"Aude Houchard","is_ca":false},{"name":"Mickael Löthgren","is_ca":false},{"name":"Alisha Monnette","is_ca":false},{"name":"Yunfei Wang","is_ca":false},{"name":"Valérie Perrot","is_ca":false},{"name":"Aly‐Khan A. Lalani","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01650825833743548,"gpt":0.2769879987711579,"spread":0.2604797404337224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003486917,0.0002044931,0.0007033166,0.0007544535,0.0003979778,0.001179431,0.000432176,0.0005486644,0.001156645],"category_scores_gemma":[0.01013007,0.0002149849,0.00101352,0.001350067,0.0004348155,0.001038812,0.0006398704,0.0009695616,0.0002272214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001297831,"about_ca_system_score_gemma":0.0005588876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002428714,"about_ca_topic_score_gemma":0.002629932,"domain_scores_codex":[0.9972233,0.001135462,0.0004441104,0.0005100738,0.0004286597,0.0002583971],"domain_scores_gemma":[0.9873094,0.002142286,0.008761887,0.0004021124,0.0006469867,0.0007372737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002100986,0.0001935632,0.9936009,0.00008792075,0.000358174,0.0001188684,0.0001383703,0.0003000263,0.00007640232,0.00004779471,0.000251402,0.002725573],"study_design_scores_gemma":[0.0001831214,0.001933435,0.9948128,0.00005535704,0.0002829108,0.0006067182,0.0002734546,0.0006401721,0.0001455468,0.00009972072,0.0009388976,0.00002788631],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968339,0.001074171,0.0001084348,0.000134797,0.0000127779,0.0000394403,0.001277379,0.000003130453,0.0005160123],"genre_scores_gemma":[0.998269,0.0001984151,0.0001017375,0.0000658891,0.00002130165,0.00003473191,0.001239166,0.000002035734,0.00006777027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003486917,"threshold_uncertainty_score":0.01844078,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3186123873","doi":"10.3233/kca-210116","title":"Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Kidney Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Nephrectomy; Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunohistochemistry; Oncology; Proportional hazards model; Internal medicine; Kidney cancer; Cancer; Metastasis; Clear cell; Pathology; Kidney","authors":[{"name":"Bimal Bhindi","is_ca":false},{"name":"Elizabeth Bearrick","is_ca":false},{"name":"John C. Cheville","is_ca":false},{"name":"Christine M. Lohse","is_ca":false},{"name":"Ross Mason","is_ca":true},{"name":"Paras Shah","is_ca":false},{"name":"Susan M. Harrington","is_ca":false},{"name":"Henan Zhang","is_ca":false},{"name":"Haidong Dong","is_ca":false},{"name":"Stephen A. Boorjian","is_ca":false},{"name":"R. Houston Thompson","is_ca":false},{"name":"Bradley C. Leibovich","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01467300630576564,"gpt":0.2340668076723973,"spread":0.2193938013666316,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023546,0.0001403913,0.0002220915,0.0004161722,0.0002281601,0.0003041769,0.0001622205,0.0002352495,0.001145082],"category_scores_gemma":[0.001087493,0.0001067486,0.0001766841,0.0004059804,0.0001963432,0.0002177935,0.0002019268,0.0002984187,0.0001240053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000196514,"about_ca_system_score_gemma":0.0001605447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009417905,"about_ca_topic_score_gemma":0.001426907,"domain_scores_codex":[0.9998518,0.00003163786,0.00001365418,0.00003406655,0.00004061483,0.00002813624],"domain_scores_gemma":[0.999332,0.0001329426,0.0003220595,0.00002309685,0.00006941897,0.0001204137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002511019,0.00001533304,0.996455,0.000009523642,0.00002244478,0.0001357063,0.00002403105,0.00005984042,0.001569076,0.000008440569,0.00005821867,0.00139139],"study_design_scores_gemma":[0.000007708891,0.00009317679,0.9984847,0.000002191751,0.00002630156,0.0006486945,0.00004991449,0.0002662199,0.0002943432,0.00001950756,0.0001052333,0.000002058481],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995852,0.0002017246,0.00005011645,0.00001892119,0.000001876756,0.000001395103,0.00004205066,0.00000207186,0.00009658714],"genre_scores_gemma":[0.9998218,0.00003872131,0.00002638404,0.000005935444,0.000005302687,0.000001808267,0.00005878932,5.744488e-7,0.00004061807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001145082,"threshold_uncertainty_score":0.003830731,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}